Syntis Bio, a 2022-spawned biotechnology startup, is taking a radically innovative approach to obesity treatment. With ARC-003, that’s exactly what they hope to do—create an experimental daily pill that takes the positive effects of gastric bypass surgery and mimics them. Entrepreneurs Rahul Dhanda, Giovanni Traverso, and Robert Langer started the company. Their goal is to develop a first-of-its-kind first-line treatment for adults with obesity that would transform the standard of care.
Suggestions were based on extensive research by Traverso and Langer at the Massachusetts Institute of Technology (MIT). Their successful discovery led them to create the complex pill formula. This drinkable digestant solution formulates to go straight to the small intestine, using a patented polymer coating created from dopamine and hydrogen peroxide. This coating procedure deposits a protective coating that acts as a thin film on the intestinal lining, lasting for about 24 hours.
In animal studies, Syntis Bio’s drug demonstrated a consistent weight loss of about 1 percent per week over a six-week period. In this regard, all of the studies demonstrated something extraordinary. During this weight loss, the drug was able to preserve 100 percent of lean muscle mass. These promising results suggest that the medication could benefit individuals seeking effective weight management solutions without compromising their muscle health.
Syntis Bio recently completed a first-in-human pilot study with nine participants. In those nearly 800 participants, the primary outcome was met with the drug shown to be safe and well-tolerated—with no adverse effects reported. This first success establishes a firm foundation for the next steps of research and, eventually, new applications that could help combat obesity.
The findings from these studies were presented at the European Congress on Obesity and Weight Management, where they generated interest among experts in the field. Syntis Bio’s CEO, Rahul Dhanda, spoke to the importance of their compound in today’s evolving field of obesity drugs.
“I think Syntis’ compound fits in perfectly as a treatment that could be used early on. It’s a kind of thing you could use as a first-line medication,” – Louis Aronne, clinical adviser to Syntis Bio.
In a conversation moderated by PBS’s VickyContinue reading marked as private, , , , ,
“When nutrients are redirected to later in the intestine, you’re activating pathways that lead towards satiety, energy expenditure, and overall healthy, sustainable weight loss,” – Rahul Dhanda.
The polymer coating is intended to be transient. It’s both effective and safe, not remaining in the gastrointestinal tract longer than needed. Giovanni Traverso explained this aspect further, stating,
“This material is something you would take as a capsule or liquid, but the next day it’s gone because of the natural turnover of our mucosal surface in the GI tract.”
Though these preliminary studies are promising, researchers warn of adverse effects. Kushnir expressed his eagerness for some gastrointestinal side effects as larger trials start.
“My anticipation is that this is going to have some digestive side effects like bloating and abdominal cramping, as well as potentially some diarrhea and nausea once it gets into a bigger study,” – Vladimir Kushnir.
Now, Syntis Bio has just released GREAT new pil on Obesity treatement! This is an ideal option for those who do not qualify for or wish to avoid surgical interventions such as gastric bypass. The organization’s continued research will help further optimize this treatment while continually assessing the efficacy and safety in bigger populations.
Obesity affects at least 650 million adults and more than 340 million children and adolescents around the globe. Breakthroughs like those being developed by Syntis Bio will be critical in addressing this growing public health crisis. The company’s efforts are emblematic of a larger movement toward addressing an increasing demand for effective, accessible weight management strategies.
Leave a Reply